ABIVAX Société Anonyme (0RA9.L)

EUR 7.35

(-0.34%)

Operating Expenses Summary of ABIVAX Société Anonyme

ABIVAX Société Anonyme's latest annual operating expenses in 2023 was 127.37 Million EUR , up 132.06% from previous year.
ABIVAX Société Anonyme's latest quarterly operating expenses in 2024 Q2 was 86.78 Million EUR , down 0.0% from previous quarter.
ABIVAX Société Anonyme reported a annual operating expenses of 56.57 Million EUR in annual operating expenses 2022, up 8.73% from previous year.
ABIVAX Société Anonyme reported a annual operating expenses of 52.03 Million EUR in annual operating expenses 2021, up 31.63% from previous year.
ABIVAX Société Anonyme reported a quarterly operating expenses of 39.2 Million EUR for 2023 Q2, down 0.0% from previous quarter.
ABIVAX Société Anonyme reported a quarterly operating expenses of 95.59 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Operating Expenses Chart of ABIVAX Société Anonyme (2023 - 2013)

Historical Annual Operating Expenses of ABIVAX Société Anonyme (2023 - 2013)

Year	Operating Expenses	Operating Expenses Growth
2023	127.37 Million EUR	132.06%
2022	56.57 Million EUR	8.73%
2021	52.03 Million EUR	31.63%
2020	39.52 Million EUR	19.08%
2019	33.19 Million EUR	593.59%
2018	4.78 Million EUR	23.26%
2017	3.88 Million EUR	7.77%
2016	3.6 Million EUR	-14.17%
2015	4.19 Million EUR	-51.4%
2014	8.63 Million EUR	18.14%
2013	7.31 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	86.78 Million EUR	0.0%
2023 Q2	39.2 Million EUR	0.0%
2023 Q4	95.59 Million EUR	0.0%
2023 FY	131.28 Million EUR	132.06%
2022 Q4	37.98 Million EUR	0.0%
2022 FY	56.57 Million EUR	8.73%
2022 Q2	18.58 Million EUR	0.0%
2021 FY	52.03 Million EUR	31.63%
2021 Q4	25.56 Million EUR	0.0%
2021 Q2	26.5 Million EUR	0.0%
2020 Q4	23.35 Million EUR	0.0%
2020 Q2	16.17 Million EUR	0.0%
2020 FY	39.52 Million EUR	19.08%
2019 Q2	17.16 Million EUR	0.0%
2019 FY	33.19 Million EUR	593.59%
2019 Q4	16.03 Million EUR	0.0%
2018 Q4	2.54 Million EUR	0.0%
2018 FY	4.78 Million EUR	23.26%
2018 Q2	2.23 Million EUR	0.0%
2017 Q2	1.85 Million EUR	0.0%
2017 FY	3.88 Million EUR	7.77%
2017 Q4	2.02 Million EUR	0.0%
2016 Q4	1.8 Million EUR	0.0%
2016 Q2	1.8 Million EUR	0.0%
2016 FY	3.6 Million EUR	-14.17%
2015 FY	4.19 Million EUR	-51.4%
2015 Q4	2.58 Million EUR	0.0%
2015 Q2	1.61 Million EUR	0.0%
2014 Q4	2.4 Million EUR	200100.0%
2014 Q2	303 Thousand EUR	200100.0%
2014 Q1	-151.50 EUR	0.0%
2014 FY	8.63 Million EUR	18.14%
2014 Q3	-1202.50 EUR	-100.4%
2013 FY	7.31 Million EUR	0.0%

Peer Operating Expenses Comparison of ABIVAX Société Anonyme

Name	Operating Expenses	Operating Expenses Difference
Boiron SA	317.27 Million EUR	59.853%
Laboratorios Farmaceuticos Rovi, S.A.	263.09 Million EUR	51.585%
Vetoquinol SA	217.11 Million EUR	41.333%
Valneva SE	134.92 Million EUR	5.594%
AB Science S.A.	14.01 Million EUR	-808.79%
Nanobiotix S.A.	62.98 Million EUR	-102.226%
PHAXIAM Therapeutics S.A.	24.98 Million EUR	-409.789%
Vivoryon Therapeutics N.V.	24.69 Million EUR	-415.859%
BioSenic S.A.	7.58 Million EUR	-1579.757%
Formycon AG	23.73 Million EUR	-436.704%